The Business of Biofabrication

Boston-based Linton Lifesciences launches this week with a patient-first mission: replace today’s underperforming vascular grafts with bioprinted grafts that help people “do more of what they love.” By combining advanced chemistry, robotics, and 3D bioprinting, the company aims to build grafts that give dialysis and vascular-disease patients extra years of quality life and time they can devote to family, work, and mobility.

At the core of Linton’s platform is a hybrid manufacturing workflow that deposits both synthetic polymers and human biomaterials in a single, continuous build. Bioprinting lets the team dial in flexibility for repeated cannulation while preserving the mechanical strength required to resist kinking, infection, and early failure. The first product targets hemodialysis access, but the underlying architecture is being designed with the potential to expand to other areas such as peripheral and pediatric indications in mind.

The founding team brings deep experience in biofabrication and commercialization. CEO Ricky Solorzano, a co-founder of BioBots/Allevi, helped popularize desktop bioprinters in hundreds of research labs. CTO Julio Aleman, Ph.D. is a published expert in microvascular printing and organ-on-chip systems, while VP of Science, Y. Shrike Zhang, Ph.D. is a bioprinting expert at Brigham and Women’s and Harvard Medical School Professor. Adam Jakus, Ph.D., previous co-founder of Dimension Inx and current CEO of Pro Therapuetics, rounds out the BioFab advisory bench.

Clinical and market guidance comes from an equally seasoned team of expert advisors: vascular-surgery innovator C. Keith Ozaki, M.D.; dialysis-access authority John Ross, M.D.; reimbursement advocate Terry Litchfield; former FDA officer Robert Lee, M.D.; and commercialization strategist Geoffrey Beecher. Their collective expertise spans predicate selection, 510(k) pathways, payer dynamics, and go-to-market execution, key hurdles on the road to first-in-human grafts.

With a technology stack capable of fusing human biomaterials and high-performance polymers, and a leadership group that pairs bench-top ingenuity with regulatory and commercial savvy, Linton Lifesciences enters the public eye as one of the more comprehensively assembled vascular-graft startups in recent memory. If the team can translate its approach from prototype to clinical reality, it may not just extend graft patency it could redefine how biofabricated implants are brought to patients.

For more info, visit www.linton.life